A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

Inclusion Criteria: * Participants definitively diagnosed with cardiac Fabry disease (who fulfill all of the following criteria) * In the case of male participants, documented plasma or leukocyte alpha-galactosidase A (α-GAL) activity was no more than 20 percent (%) of normal value (except for heterozygous female participants) * Left ventricular hypertrophy was noted. * Accumulation of globotriaosylceramide (GL-3) in the myocardium or a genetic deficiency associated with α-GAL was confirmed * Or in the case of heterozygous female participants, when the family (father or son) was diagnosed with Fabry disease. (Father or son was related by birth.) * Without symptoms or signs of Fabry, such as acroparesthesia, angiokeratomas, abnormal sweating, pain of distal extremities, chronic abdominal pain/diarrhea and corneal opacities were observed, except for proteinuria sign. * Participants with interventricular and posterior wall thickness of at least 13 millimeter (mm) on echocardiography within 3 months before signed date to informed consent * Participants in whom cardiac function was rated as Class I or II according to the New York Heart Association (NYHA) classification when giving informed consent. * Participants classification: inpatients and outpatients * Participants who had given written informed consent before the study-related baseline tests. Exclusion Criteria: * Participants with severe hypertension (for example, blood pressure more than or equal to 180 millimeter of mercury \[mmHg\] and/or blood pressure more than or equal to 110 mmHg in spite of adequate medication) * Participants whose serum creatinine level was higher than the upper normal limit within 3 months (12 weeks) prior to giving informed consent. * Participants who had undergone kidney transplantation or were currently on dialysis. * Participants with any serious hepatic disorder. Participants who had abnormal hepatic function test values within 3 months (12 weeks) prior to giving informed consent (when either alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] level exceeded the value five times as high as the upper normal limit). * Permanent pacemaker or defibrillator implanted participants * Pregnant or lactating women * Participants who had taken this drug for 6 months (26 weeks) or more before giving informed consent. * Participants who had participated in a clinical study employing any other investigational product within 3 months prior to giving informed consent. * Enzyme replacement therapy history, except for agalsidase beta * Participants who were unwilling to comply with the requirements of the protocol. * Others judged by the investigator or sub-investigator to be ineligible for the study